Firsocostat
Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976.[1] It was discovered by Nimbus Therapeutics.[2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease.[3]
Names | |
---|---|
IUPAC name
2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
DrugBank | |
KEGG | |
PubChem CID |
|
UNII | |
| |
| |
Properties | |
C28H31N3O8S | |
Molar mass | 569.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
References
- Alkhouri, Naim; Lawitz, Eric; Noureddin, Mazen; DeFronzo, Ralph; Shulman, Gerald I. (1 February 2020). "GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (2): 135–141. doi:10.1080/13543784.2020.1668374.
- Harriman, Geraldine; Greenwood, Jeremy; Bhat, Sathesh; Huang, Xinyi; Wang, Ruiying; Paul, Debamita; Tong, Liang; Saha, Asish K.; Westlin, William F.; Kapeller, Rosana; Harwood, H. James (29 March 2016). "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats". Proceedings of the National Academy of Sciences. 113 (13). doi:10.1073/pnas.1520686113.
- Alkhouri, Naim (1 February 2020). "NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges". Expert Opinion on Investigational Drugs. 29 (2): 87–87. doi:10.1080/13543784.2020.1721169.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.